These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 28408529)

  • 1. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
    J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
    Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
    J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Hohenfellner M; Giesel FL; Haberkorn U; Morgenstern A
    J Nucl Med; 2018 May; 59(5):795-802. PubMed ID: 29326358
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted alpha therapy of mCRPC: Dosimetry estimate of
    Kratochwil C; Schmidt K; Afshar-Oromieh A; Bruchertseifer F; Rathke H; Morgenstern A; Haberkorn U; Giesel FL
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):31-37. PubMed ID: 28891033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience with [
    Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
    J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 9. 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.
    Vatsa R; Sood A; Vadi SK; Das CK; Kaur K; Parmar M; Mittal BR
    Clin Nucl Med; 2020 Jun; 45(6):437-438. PubMed ID: 32366786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Clinical Results for PSMA-Targeted α-Therapy Using
    Zacherl MJ; Gildehaus FJ; Mittlmeier L; Böning G; Gosewisch A; Wenter V; Unterrainer M; Schmidt-Hegemann N; Belka C; Kretschmer A; Casuscelli J; Stief CG; Unterrainer M; Bartenstein P; Todica A; Ilhan H
    J Nucl Med; 2021 May; 62(5):669-674. PubMed ID: 33008928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem Isotope Therapy with
    Meyer C; Stuparu A; Lueckerath K; Calais J; Czernin J; Slavik R; Dahlbom M
    J Nucl Med; 2023 Nov; 64(11):1772-1778. PubMed ID: 37797974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry Estimate and Initial Clinical Experience with
    Rathke H; Flechsig P; Mier W; Bronzel M; Mavriopoulou E; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
    J Nucl Med; 2019 Jun; 60(6):806-811. PubMed ID: 30389816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing
    Rathke H; Kratochwil C; Hohenberger R; Giesel FL; Bruchertseifer F; Flechsig P; Morgenstern A; Hein M; Plinkert P; Haberkorn U; Bulut OC
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):139-147. PubMed ID: 30151743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetry of
    Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
    [No Abstract]   [Full Text] [Related]  

  • 20. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 35.